Expert Review of Anticancer Therapy最新文献_第9页

Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies. 鼻咽癌放射性鼻咽坏死合并局部复发：诊断与治疗策略。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-08 DOI: 10.1080/14737140.2024.2433265

Gui-Qiong Xu, Rui You, Chao Lin, Yu-Long Xie, Li-Zhi Liu, Feng Lei, Ming-Yuan Chen

{"title":"Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies.","authors":"Gui-Qiong Xu, Rui You, Chao Lin, Yu-Long Xie, Li-Zhi Liu, Feng Lei, Ming-Yuan Chen","doi":"10.1080/14737140.2024.2433265","DOIUrl":"10.1080/14737140.2024.2433265","url":null,"abstract":"Background: To identify the diagnosis and treatment strategies by analyzing the clinical characteristics and treatment methods of RNNCLR.Methods: A total of 210 patients pathologically diagnosed with RNNCLR were retrospectively included. Clinical characteristics, MRI features, treatment methods, and survival outcomes were analyzed. Propensity score matching (PSM) analysis was performed to adjust the surgical benefit.Results: Ninety-one patients (43.3%) took a single biopsy, 67 patients (31.9%) underwent repeated biopsies and 52 patients (24.8%) received endoscopic surgery to obtain pathological positive tissues. RNNCLR had characteristic imaging features distinguished from pure radiation necrosis. The interval from the previous radiotherapy was 13.2 (7.0, 23.3) months. The 1-year, 3-year, and 5-year overall survival rates were 59.6%, 32.3%, and 14.6%. Patients with reirradiation, detectable EBV-DNA level, or ICA exposure had a worse prognosis. Overall survival was significantly higher in the endoscopic surgery group than in nonsurgery group after PSM (3-year OS rates, 44.5% vs. 23.9%, p = 0.011).Conclusions: Histopathological diagnosis of RNNCLR needs repeated biopsies or even surgery. Careful analysis of MRI images, correlation with interval time from last radiation, and short-term follow-up may solve the diagnostic dilemmas. Endoscopic surgery results in a survival benefit by completely resecting lesions or removing necrotic tissue to reduce necrosis-related complications.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1293-1301"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis. 循环长非编码RNA对结直肠癌癌症患者的预后价值：一项荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2023-11-15 DOI: 10.1080/14737140.2023.2280643

Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li

{"title":"Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis.","authors":"Bin Hu, Yanfei Zhang, Bingjing Jiang, Angcheng Li","doi":"10.1080/14737140.2023.2280643","DOIUrl":"10.1080/14737140.2023.2280643","url":null,"abstract":"Objectives: This meta-analysis aimed to evaluate the prognostic significance of circulating long non-coding RNAs (lncRNAs) in colorectal cancer (CRC).Methods: A comprehensive literature search was conducted in databases (Embase, Web of Science, PubMed, and Cochrane Library) up to July 2022. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed with Review Manager 5.4 and Stata 17.0. Publication bias was assessed using Begg's test, and sensitivity analysis was conducted to validate the meta-analysis results.Results: Ten articles, comprising 1,473 CRC patients and 18 different circulating lncRNAs, were included. Thirteen circulating lncRNAs were found to be up-regulated in CRC patients, while five were down-regulated. High expression of circulating lncRNAs up-regulated in CRC patients was associated with shorter CRC OS (HR = 2.91, 95% CI: 1.17, 7.22; P = 0.02, I2 = 86%). Conversely, high expression of circulating lncRNAs down-regulated in CRC patients was linked to longer CRC OS (HR = 0.16, 95% CI: 0.07, 0.40; P < 0.0001, I2 = 0%) and improved DFS (HR = 0.52, 95% CI: 0.37, 0.74; P = 0.0002, I2 = 0%). Additionally, circulating lncRNA levels correlated with TNM staging, tumor location, and lymph node metastasis.Conclusion: Circulating lncRNAs show promise as prognostic markers for CRC patients, but further studies are warranted to validate these findings.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1249-1259"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NRF2/KEAP1 signaling inhibitors in gynecologic cancers. NRF2/KEAP1信号抑制剂在妇科癌症中的作用。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-07 DOI: 10.1080/14737140.2024.2438951

Sonia Fantone, Daniela Marzioni, Giovanni Tossetta

引用次数: 0

The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis. 维利帕尼联合化疗治疗肺癌的疗效：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-10-20 DOI: 10.1080/14737140.2024.2417770

Muataz Kashbour, Abdulhameed Alhadeethi, Sara Awwad, Mazen Yassin, Ahmed Amin, Mohamed Abed, Abubaker Abdelmalik, Yasmeen Jamal Alabdallat

{"title":"The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis.","authors":"Muataz Kashbour, Abdulhameed Alhadeethi, Sara Awwad, Mazen Yassin, Ahmed Amin, Mohamed Abed, Abubaker Abdelmalik, Yasmeen Jamal Alabdallat","doi":"10.1080/14737140.2024.2417770","DOIUrl":"10.1080/14737140.2024.2417770","url":null,"abstract":"Objective: This meta-analysis aims to examine the effectiveness of veliparib, a poly ADP-ribose polymerase inhibitor, in combination with chemotherapy in treating bronchogenic carcinoma.Methods: PubMed, Cochrane, Scopus, and Web of Science were searched for eligible randomized controlled trials comparing veliparib plus chemotherapy to standard chemotherapy in adult lung cancer patients, until July 2023. The main outcomes were overall survival (OS) and progression-free survival (PFS).Results: This meta-analysis included six studies encompassing 2,136 patients. Veliparib has a slight OS improvement over placebo, HR = 0.91, 95% CI [0.83 to 1.0], p = 0.05. Veliparib offers more OS benefit in the subpopulation of non-small cell lung cancer (NSCLC) than small-cell lung cancer (SCLC), HR = 0.89, 95% CI [0.81,0.99], p = 0.03 and HR = 1.00, 95% CI [0.79, 1.28], p = 0.97, respectively. There was no significant PFS benefit between the two groups, HR = 0.92, 95% CI [0.81-1.01], p = 0.08).Conclusion: Veliparib has a marginal inclination for overall survival improvement, more so in NSCLC, with an acceptable safety profile. Our results merit the pursuit of better-powered trials to support further the extent of veliparib's effectiveness in lung cancer patients.Registration: PROSPERO (CRD42023453705).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1237-1247"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis. 胃癌中 TIMP1 表达的临床病理和预后意义：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408278

Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu

{"title":"Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.","authors":"Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu","doi":"10.1080/14737140.2024.2408278","DOIUrl":"10.1080/14737140.2024.2408278","url":null,"abstract":"Background: The research on the associations between tissue inhibitors of metalloproteinase-1 (TIMP1) expression and the clinicopathological characteristics and prognosis of patients with gastric cancer (GC) have resulted in contradictory findings. Exploring the associations between TIMP1 and clinicopathological parameters and the prognosis of GC patients is essential.Methods: We searched the literature in the databases according to the inclusion and exclusion criteria. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the relationships between TIMP1 expression and the clinicopathological parameters and prognosis of GC patients.Results: Nine studies with 1,200 GC patients were included. Our results indicated that TIMP1 expression was not related to sex, age, TNM stage, depth of invasion, lymph node metastasis, or tumor size in GC patients. However, TIMP1 expression was associated with the differentiation of GC. Furthermore, TIMP1 expression was associated with poor prognosis in GC patients.Conclusion: TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1169-1176"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interventions to reduce the risk of side-effects of cancer treatments in childhood. 降低儿童癌症治疗副作用风险的干预措施。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1080/14737140.2024.2411255

Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali

{"title":"Interventions to reduce the risk of side-effects of cancer treatments in childhood.","authors":"Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali","doi":"10.1080/14737140.2024.2411255","DOIUrl":"10.1080/14737140.2024.2411255","url":null,"abstract":"Introduction: Childhood cancers as a group affect around 1 in 500 children but each individual diagnosis is a rare disease. While research largely focuses on improving cure rates, the management of side effects of treatment are high priority for clinicians, families and children and young people.Areas covered: The prevention and efficient management of infectious complications, oral mucositis, nausea and vomiting and graft-vs-host disease illustrated with examples of implementation research, translation of engineering to care, advances in statistical methodologies, and traditional bench-to-patient development. The reviews draw from existing systematic reviews and well conducted clinical practice guidelines.Expert opinion: The four areas are driven from patient and family priorities. Some of the problems outlined are ready for proven interventions, others require us to develop new technologies. Advancement needs us to make the best use of new methods of applied health research and clinical trial methodologies. Some of the greatest challenges may be those we're not fully aware of, as new therapies move from their use in adult oncological practice into children. This will need us to continue our collaborative, multi-professional, multi-disciplinary and eclectic approach.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1117-1129"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. 骨髓增生异常综合征/肿瘤（MDS）的靶向疗法：当前形势与未来方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-17 DOI: 10.1080/14737140.2024.2414071

Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan

{"title":"Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.","authors":"Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/14737140.2024.2414071","DOIUrl":"10.1080/14737140.2024.2414071","url":null,"abstract":"Introduction: Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) categories. Until recently, LR-MDS has been typically managed by supportive measures and erythropoiesis-stimulating agents (ESAs); whereas management of HR-MDS typically included hypomethylating agents and allogeneic hematopoietic stem cell transplant. However, the limited rates and durations of response observed with these interventions prompted the search for targeted therapies to improve the outcomes among patients with MDS.Areas covered: Here, we review the current landscape of targeted therapies in MDS. These include pyruvate kinase and hypoxia-inducible factor (HIF) activators; TGF-beta, telomerase, BCL2 and isocitrate dehydrogenase (IDH) inhibitors; as well as novel approaches targeting inflammation, pyroptosis, immune evasion, and RNA splicing machinery.Expert opinion: This review highlights the progress and challenges in MDS treatment. Despite some promising results, many therapies remain in early development or have faced setbacks, emphasizing the need for a more comprehensive understanding of the disease's pathobiology. Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1131-1146"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future investigative directions for novel therapeutic targets in head and neck cancer. 头颈癌新型治疗靶点的未来研究方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-16 DOI: 10.1080/14737140.2024.2417038

Jacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, Jennifer R Grandis

引用次数: 0

Treatment of skin cancers in solid organ transplant recipients: current status and future perspectives. 实体器官移植受者皮肤癌的治疗：现状与未来展望。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408280

Emilie Ducroux, Jean Kanitakis

引用次数: 0

Infrared radiation for cancer hyperthermia: the light to brighten up oncology. 用于癌症热疗的红外线辐射：照亮肿瘤学的明灯。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/14737140.2024.2416063

Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu

{"title":"Infrared radiation for cancer hyperthermia: the light to brighten up oncology.","authors":"Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu","doi":"10.1080/14737140.2024.2416063","DOIUrl":"10.1080/14737140.2024.2416063","url":null,"abstract":"Introduction: Cancer constitutes the greatest public health threat to humans, as its incidence and mortality rates continue to increase worldwide. With the development of medical physics, more practitioners focus on the direct and indirect anti-tumor effects of physical factors. Infrared radiation (INR) is currently the most rapidly developing physical therapy method for tumors and has become a favored target for many oncologists and researchers owing to its advantages of high efficiency, low toxicity, and strong feasibility.Areas covered: This work provides a comprehensive collection of the latest information on INR anti-tumor research, drawing from public medical databases (PubMed, Web of Science, Embase, and Clinical Trials) from the last 10 years (2014 to 2024), and encompassing both basic and clinical research in oncology and physics. This article reviews the application of INR in tumor hyperthermia, summarizes and analyzes the practical value of INR for tumor treatment, and discusses future development trends to provide valuable assistance for the subsequent development of oncology.Expert opinion: Currently, INR has continuously accumulated excellent data in the field of tumor hyperthermia, bringing practical survival benefits to patients with cancer, and playing an important role in basic and clinical cancer research.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1147-1160"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0